Systemic inflammatory responses in patients with acute otitis media and the impact of treatment with sinupret.
The systemic inflammatory responses and the impact of sinupret therapy have been investigated in 14 patients with acute otitis media, AOM. The age of inspected individuals covered a range of 29.0+/-12.3 years. The blood samples were taken at the admission and after ten days treatment with sinupret. The dosage of sinupret application was two tablets or 50 drops three times per day. Utilizing the technique of enzymelinked immunoassays, the concentrations of two cytokines, TNF-alpha and IL-6, were measured in the blood serum. The minimum detectable amount of cytokines was less then 2.5 pg/ml. Age-matched five healthy subjects without significant medical history served for controls. The study proved an existence of systemic inflammatory responses under the AOM. In AOM patients as compared with healthy individuals the concentrations of both cytokines were elevated, although the difference reached the statistically significant level with respect to TNF-alpha but not to IL-6. After treatment with sinupret, the TNF-alpha level dropped noticeably, proving a recovery from the pathology. IL-6 displayed a similar pattern, although the difference between pre- and post-treatment samples was statistically nonsignificant. Assessment of varies cytokines and proper establishment of their profiles could detect more specific marker(s) of AOM of both bacterial or viral etiology and could promote thus a precise prediction of the outcome of the pathology. Generally, the estimation of cytokines under AOM could offer a powerful tool for the objective evaluation of efficacy of treatment and for the avoidance of the ineffective drug therapy.
Chkhaidze
I
I
Tbilisi State Medical University, Tbilisi.
Nemsadze
K
K
Gotsadze
K
K
Nikoleishvili
E
E
Gordeladze
G
G
D000208:Acute Disease; D000328:Adult; D016207:Cytokines / Q000187:drug effects*; D006801:Humans; D007249:Inflammation / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D015850:Interleukin-6 / Q000378:metabolism; D010033:Otitis Media / Q000188:drug therapy* / Q000276:immunology* / Q000382:microbiology; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D016207:Cytokines; D015850:Interleukin-6; D010936:Plant Extracts; D014409:Tumor Necrosis Factor-alpha; C028353:Sinupret